SCHEMBL4025977

SCHEMBL4025977

CCOC(CCOC(C)C)c1ccc(OCc2nc(-c3ccccc3)oc2C)cc1

nearest known ligand 0.52

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 14/20 0.52
PPARG P37231 14/20 0.52
FFAR1 O14842 1/20 0.51
KDR P35968 1/20 0.48
MAPT P10636 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4028565 0.92 FFAR1 (0.53) PPARAPPARGFFAR1KDRMAPT
SCHEMBL4030774 0.91 FFAR1 (0.52) PPARAPPARGFFAR1KDR
SCHEMBL4026013 0.90 FFAR1 (0.54) PPARAPPARGFFAR1KDRMAPT
SCHEMBL4028342 0.89 PPARA (0.51) PPARAPPARGFFAR1KDRMAPT
SCHEMBL4026911 0.89 FFAR1 (0.56) PPARAPPARGFFAR1KDRMAPT
SCHEMBL4027562 0.88 FFAR1 (0.53) PPARAPPARGFFAR1KDRMAPT
SCHEMBL4026189 0.87 FFAR1 (0.50) PPARAPPARGFFAR1KDRMAPT
SCHEMBL4033080 0.87 PPARG (0.50) PPARAPPARGFFAR1KDRMAPT
SCHEMBL4031984 0.85 PPARG (0.51) PPARAPPARGFFAR1KDRMAPT
SCHEMBL4031222 0.85 FFAR1 (0.50) PPARAPPARGFFAR1KDRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP claimed
US-20060142277-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED 2006-06-29 US claimed
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP disclosed
US-20060142277-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142277-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 PPARA 2339/4885PPARG 2043/4885FFAR1 2147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.